Jefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $52.00 (from $57.00) while maintaining a Buy rating following results.

Analyst David Steinberg trimmed FY17 Exparel revs by $8M to $283M to align with the midpoint of updated guidance.They also trim FY18-20 sales ests by 4-6%